spacer
home > pmps > summer 2009 > securing blisterpacks
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Securing Blisterpacks

The pharmaceutical industry produces billions of blisterpacks each year. Not only is the quality and efficacy of the pack important, but also its security, both within the production process and throughout the supply chain to the patient. The blisterpack is the most common packaging presentation for solid dose medicines today in the UK and in the majority of European countries. The blisterpack is the pack of choice for many reasons:

  • All the required legislative text is clearly laid out on the outer carton for the regulators
  • The large surface area of the carton maximises the brand opportunities for marketers
  • The product name and strength is displayed in a large clear font on the cartons for pharmacists and nurses
  • Patients find it easy to use, especially if the blister foil is printed with the days of the week, enabling them to see if they have taken a dose or not

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Cathy Brown is a Process Improvement Manager at Napp Pharmaceuticals Limited in Cambridge, UK. She is a qualified pharmacist and member of the Royal Pharmaceutical Society of Great Britain. After qualifying as a pharmacist and spending two years working in hospital pharmacies in London and Cambridge, she joined Napp Pharmaceuticals as Production Pharmacist in 1985. Since joining, she has worked within the production environment, specialising in maintaining compliance to EU packaging directives and other legislation. She has specialised in control and security of products and packs, new pack introduction projects involving product launches around the world, and other blisterpacking process improvement projects.
spacer
Cathy Brown
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ERT Offers First Patient-Administered ECG Assessment for Continuation of Clinical Trials during COVID-19

ERT, a global data and technology company that captures critical endpoint data while minimizing uncertainty and risk in clinical trials, today announced a first-of-its-kind partnership with AliveCor, the leader in AI-based, personal ECG technology. The partnership enables ERT to capture digital cardiac safety data with KardiaMobile 6L, the only FDA-cleared personal ECG for patient-administered 6-lead data collection.
More info >>

White Papers

Six Strategies to Stretch Your Limited Drug Supply for Clinical Studies

PCI Pharma Services

Bringing a new drug to market can be a heavy financial burden on any pharmaceutical company. It has become even more burdensome over the last several years as the industry pushes the boundaries of innovation. This is because newer, often more-complex therapies not only increase risk in drug development but also drive costs even higher. A recent analysis of the investment needed to develop a new prescription medicine shows the total cost can be as high as $2.6 billion (1). That number becomes even more staggering when you consider the fact that only about 12 percent of drug candidates that make it to Phase I testing are eventually approved by the FDA (2). The investment companies lose as a result may be too devastating to their bottom line to ever recover.
More info >>

 
Industry Events

INTERPHEX 2020

15-17 July 2020, Javits Center NYC


More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement